Abstract: Novel carboximidamide derivatives represented by the following formula (A) and acid adduct salts thereof are disclosed: ##STR1## wherein all the substituents have the same meanings as defined above. N-cyano-pyridinecarboximidate compounds represented by the following formula (II) which are the intermediates for preparing of N-cyano-N'-substituted-pyridinecarboximidamide derivatives wherein the substituent B in the above described formula (A) is pyridine are also disclosed: ##STR2## wherein all the substituents have the same meanings as defined above. The process for preparing the compounds, the pharmaceutical agents comprising the compound having vasodilating effect, and the therapeutic method of dosing the compound on patients for therapy are also disclosed.

Abstract: Novel carboximidamide derivatives represented by the following formula (A) and acid adduct salts thereof are disclosed: ##STR1## wherein all the substituents have the same meanings as defined above. N-cyano-pyridinecarboxyimidate compounds represented by the following formula (II) which are the intermediates for preparing of N-cyano-N'-substituted-pyridinecarboximidamide derivatives wherein the substituent B in the above described formula (A) is pyridine are also disclosed: ##STR2## wherein all the substituents have the same meanings as defined above. The process for preparing the compounds, the pharmaceutical agents comprising the compound having vasodilating effect, and the therapeutic method of dosing the compound on patients for therapy are also disclosed.

Abstract: Novel carboximidamide derivatives represented by the following formula (A) and acid adduct salts thereof are disclosed: ##STR1## wherein all the substituents have the same meanings as defined above. N-cyano-pyridinecarboximidate compounds represented by the following formula (II) which are the intermediates for preparing of N-cyano-N'-substituted-pyridinecarboximidamide derivatives wherein the substituent B in the above described formula (A) is pyridine is also disclosed: ##STR2## wherein all the substitutents have the same meanings as defined above. The process for preparing the compounds, the pharmaceutical agents comprising the compound having vasodilating effect, and the therapeutic method of dosing the compound on patients for therapy are also disclosed.

Abstract: Disclosed is an anthracycline compound of the formula (I): ##STR1## wherein Ra is -R.sup.1, ##STR2## or --OR.sup.3, R.sup.1 being (1) alkyl, alkenyl, alkynyl, fluoroalkyl, aryl or aralkyl, or (2) alkyl, alkenyl, alkynyl. fluoroalkyl, aryl or aralkyl having carboxyl, azido, amino, hydroxy, alkoxy or a halogen atom; R.sup.2 being R.sup.1, a hydrogen atom or hydroxy; and R.sup.3, which may be the same or different when one substituent has two R.sup.3 's, being R.sup.1 or a hydrogen atom; or the formula (II): ##STR3## wherein Rb is -R.sup.1, ##STR4## or --OR.sup.3, R.sup.1, R.sup.2 and R.sup.3 being as defined above; and R.sup.4 being the same as R.sup.3 except that methyl is not included; or an acid addition salt thereof.This compound can be contained as an active ingredient in an antitumor agent, whereby good results are attainable.

Abstract: An anthracycline compound (13-deoxycarminomycin) selected from the group consisting of anthracycline compounds represented by the following formula ##STR1## R1 is a hydroxy group, R2 represents a hydrogen atom or a hydroxyl group,R3 is a hydrogen atom,R4 represents one of the following groups (a) to (d) ##STR2## and if R2 is hydroxyl, R4 is not (d).

Abstract: Disclosed is a process for producing a 10-hydroxyanthracycline of the following formula (II) which comprises reacting a compound of the following formula (I) or an acid addition salt thereof with an N-oxide of a tertiary amine ##STR1## wherein: R.sup.1 through R.sup.6 each designate any of H, OH and OCH.sub.3 ; R.sup.7 designates any of H, OH and a sugar residue; and R.sup.8 designates any of C.sub.2 H.sub.5, COCH.sub.3, CH(OH)CH.sub.3, CH(OH)CH.sub.2 (OH) and COCH.sub.2 OH. In accordance with this process, it is possible to efficiently introduce a hydroxyl group into the 10-position of an anthracycline having no substitutent at the same position thereof.

Abstract: An anthracycline compound, R20X2, of the following formula (II) is produced by a process which comprises subjecting an anthracycline compound, R20X3, of the following formula (I) or a salt thereof to reaction in the co-presence of (1) acetone and/or dimethylformamide and (2) an aqueous solution containing ammonium ion and/or trialkylamine. ##STR1## The anthracycline compound, R20X2, can be produced not only by the cultivation of actinomycetes but also, in accordance with the process as shown above, by chemical conversion of the anthracycline compound, R20X3, in a high yield.

Abstract: Disclosed is an anthracycline compound of the following formula (I) or an acid addition salt thereof: ##STR1## These compounds are useful as intermediates in the synthesis of an anthracycline compound, M-R20X or M-R20X2, which has antitumor activity.

Abstract: Disclosed is a novel anthracycline compound of the following formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are each a hydroxyl group or a hydrogen atom and satisfy the condition that, when R.sup.2 is a hydroxyl group, R.sup.1 is a hydroxyl group or a hydrogen atom, whereas, when R.sup.2 is a hydrogen atom, R.sup.1 is a hydrogen atom, or an acid addition salt thereof.These compounds can be contained as active ingredients in antitumor agents, whereby good results are attainable.